MSB 5.24% $1.11 mesoblast limited

the upside, page-29

  1. 30,295 Posts.
    lightbulb Created with Sketch. 1826
    Oh short memory is a problem here: how long did you compare MSB to WOW, and CBA, and a whole range of so called value investing stocks which had no relationship at all to biotechs?

    It went on, and on...and on! And then we got reprises. Eventually WOW embarrassed itself, and CBA fell a bit, and the government called in higher levels of reserves...and it all looked a bit silly really. The point is you pay a premium for getting a stock already earning high levels and BKL was cheaper when it wasn't earning high revenue, and now it's gone epic on the back of bigger news and a JV.

    Which points to another problem: opportunity cost. You wait until you see the money rolling in optimally, and you pay an optimal price. It's why I've referred to MSB as an emerging blue chip. When it is a blue chip you will pay a blue chip price. How about waiting until it reaches $100, would that be a good time to buy?

    PS the Americans are going to understand it. They have a functional and mature biotech investment culture, with powerhouse resources. I'm going to put some money on horse 22 for the Cup, just for fun.

    In any case, I feel it's a good opportunity to look at the upside of MSB. After all, we're in a trading halt. How nice!
  2. This thread is closed.

    You may not reply to this discussion at this time.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.